Authors
Qamar Abuhassan, Hamzeh J Al-Ameer, S Renuka Jyothi, Priya Priyadarshini Nayak, P Prakash, Gunjan Mukherjee, Aashna Sinha, Ozoda Hazratkulova
Published in
Immunology. Jul 22, 2026. Epub Jul 22, 2026.
Abstract
Despite significant advancements in the oncology field, lung cancer remains the leading cause of cancer-related mortality worldwide. A key contributor to the increased mortality rate is the resistance exhibited by cancer cells to standard anticancer treatments, particularly in advanced stages of the disease. Evidence indicates that chronic inflammation within the tumour microenvironment (TME) promotes tumorigenesis and contributes to resistance to immunotherapy, radiotherapy and chemotherapy. Notably, the overexpression of the cytokine interleukin-6 (IL-6) has been documented in various tumours, including lung cancer. Both tumour-associated fibroblasts (TAFs) and tumour cells constitute the predominant sources of secreted IL-6 within the TME. Various research has elucidated the role of IL-6 and its signalling pathways in facilitating therapeutic resistance, metastasis and tumour progression in lung cancer. Consequently, targeting IL-6 and/or its receptor, in conjunction with other effective anticancer treatments, represents an ideal therapeutic technique for lung cancer management. This review aims to synthesize recent evidence on the function of the IL-6/IL-6R signalling pathway in lung cancer, with a focus on its role in therapy resistance, prognosis and tumour progression, on the basis of clinical and preclinical studies.
PMID:
42484541
Bibliographic data and abstract were imported from PubMed on 22 Jul 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 7
- Comments 0